Anaerobic bacterial resistance trends may vary greatly, depending on regions or institutions (1) . The Clinical and Laboratory Standards Institute (CLSI) does not recommend routine susceptibility testing of all clinical isolates of anaerobic bacteria, except for the management of patients with serious infections (4) . A recent survey indicated that only a few laboratories in the United States performed antimicrobial susceptibility testing of anaerobic bacteria due to the complex techniques and predictable susceptibilities involved (5) . However, regional susceptibility patterns are pivotal in the empirical treatment of infected patients because these patterns are related to clinical outcomes (13) . Therefore, periodic monitoring of the regional or institutional resistance trends of clinically important anaerobe isolates is recommended (4) . Our investigation of resistance trends of Bacteroides fragilis group organisms from South Korea has been taking place since 1989 (9, 15) . However, few studies have focused on the susceptibilities of other anaerobes. Therefore, the aim of this study was to determine the recent antimicrobial resistance patterns of frequently isolated anaerobes at a tertiary-care hospital in South Korea.
Anaerobes were isolated from blood, normally sterile body fluid, and abscess specimens, but Clostridium difficile was isolated from stool specimens of suspected C. difficile-associated disease patients at Severance Hospital in 2007 and 2008. The isolates were identified by either conventional methods (19) Antimicrobial susceptibility testing was performed using the CLSI agar dilution method (4). The medium used was Brucella agar (Becton Dickinson, Cockeysville, MD) supplemented with 5 g hemin and 1 g vitamin K 1 per ml and 5% laked sheep blood. The antimicrobial powders used were piperacillin and tazobactam (Yuhan, Seoul, South Korea), cefoxitin (Merck Sharp & Dohme, West Point, PA), cefotetan (Daiichi Pharmaceutical, Tokyo, Japan), clindamycin (Korea Upjohn, Seoul, South Korea), imipenem, metronidazole (Choong Wae, Seoul, South Korea), chloramphenicol (Chong Kun Dang, Seoul, South Korea), meropenem (Sumitomo, Tokyo, Japan), moxifloxacin (Bayer Korea, Seoul, South Korea), and vancomycin (Eli Lilly & Co., Indianapolis, IN). For the combination of piperacillin and tazobactam, a constant tazobactam concentration of 4 g/ml was added.
An inoculum of 10 5 CFU was applied with a Steers replicator (Craft Machine Inc., Woodline, PA), and the plates were incubated in an anaerobic chamber (Forma Scientific, Marietta, OH) for 48 h at 37°C. The MIC of each antimicrobial agent was defined as the concentration at which there was a marked reduction in growth, such as from confluent colonies to a haze, Ͻ10 tiny colonies, or 1 to 3 normal-sized colonies. B. fragilis ATCC 25285 and B. thetaiotaomicron ATCC 29741 were used as controls.
␤-Lactamase production by anaerobic Gram-negative bacilli, with the exception of B. fragilis group organisms, was determined by applying test organisms to the Cefinase disks and recording the results after 30 min (Becton Dickinson, Cockeysville, MD). Table 1 shows the MICs of antimicrobial agents and the resistance rates of the anaerobes tested. Among the 255 isolates, B. fragilis group organisms were the most prevalent (47%). These organisms are more virulent and more resistant to antimicrobial agents than most other anaerobes (3) . In this study, piperacillin-tazobactam, cefoxitin, imipenem, and meropenem were highly active against B. fragilis group organisms, with resistance rates of less than 7%. The rates of resistance to imipenem and piperacillin-tazobactam were 4% and 7%, respectively, for other B. fragilis group organisms. However, much higher resistance rates were observed for piperacillin (27 to 51%), cefotetan (14 to 68%), and clindamycin (33 to 86%). These values were similar to those observed in 1997 to 2004 in the same hospital: piperacillin, 33 to 49%; cefotetan, 14 to 60%; clindamycin, 51 to 76% (15) . A higher prevalence of resistance, in particular to clindamycin, was observed than in the United States, i.e.,19 to 35% (17) . CLSI added a recommendation to test susceptibility to moxifloxacin in 2004 and 2007. In this study, the moxifloxacin resistance rates were 11% for B. fragilis and 18% for other B. fragilis group organisms. These rates were slightly higher than the 7 to 9% reported in Taiwan (11) but lower than those in Greece (14) and the United States (16 to 75% and 26 to 55%, respectively) (17). Overall, Prevotella, Porphyromonas, and Fusobacterium isolates are more susceptible than B. fragilis group organisms (7). Among these organisms, ␤-lactamase producers were resistant to penicillin and ampicillin (3, 7) . A recent study showed that 94% of the Prevotella isolates tested were ␤-lactamase producers, which correlated well with susceptibility to penicillin (11) . In the present study, ␤-lactamase production was detected in 26 Prevotella isolates (94%) and 1 Fusobacterium isolate (14%). While 50% of the non-P. intermedia Prevotella isolates were resistant to clindamycin, all of the P. intermedia isolates were susceptible to clindamycin. Other studies indicated that 17% and 36% of the P. intermedia isolates were resistant to clindamycin (8, 16) .
Anaerobic Gram-positive cocci account for approximately one-quarter of all isolates from anaerobic infections. They may cause various infections, including skin infections, necrotizing pneumonia, and bacteremia (18) . Several species previously placed in the genus Peptostreptococcus have been reclassified into new genera, including Anaerococcus, Finegoldia, Micrococcus, and Peptoniphilus (7). These organisms exhibited various rates of resistance to penicillin, clindamycin, and metronidazole (7) . A European surveillance study showed that the majority of the isolates found to be resistant to clindamycin and penicillin were identified as F. magna (2) . In our study, the rates of resistance of Gram-positive cocci to clindamycin and moxifloxacin varied according to species. The highest clindamycin resistance observed was 40% of A. prevotii isolates, followed by 33% of P. asaccharolyticus isolates. These rates were much higher than those reported in Europe (4%) and the United States (8%) (1, 2) but similar to the 25.9% observed in 1994 in South Korea (10) . The rates of resistance to moxifloxacin varied from 27% among F. magna isolates to 0% among P. asaccharolyticus isolates. The difference in resistance rates among anaerobic Gram-positive cocci may be of importance. The resistance patterns of these organisms could help in the selection of appropriate antimicrobial treatment options, although susceptibility testing of individual patient isolates is not performed.
C. perfringens is generally very susceptible to most antibiotics (7). The present study showed that all of the antimicrobial agents tested had high activity against this organism. C. difficile has highly variable resistance to ␤-lactams, including penicillin, cephalosporins, imipenem, clindamycin, and moxifloxacin (6, 7) . In our study, the rates of resistance to cefoxitin, clindamycin, and moxifloxacin were 100%, 85%, and 77%, respectively. The C. difficile NAP1/027 epidemic isolates were known to be resistant to moxifloxacin (12) . A high rate of resistance to moxifloxacin was observed in this study, although none of the isolates were NAP1/027 strains. Other Gram-positive bacilli, such as Actinomyces, Bifidobacterium, and Eubacterium species, are generally susceptible to ␤-lactams, including penicillin. Metronidazole-resistant isolates were common among these organisms (3). In our study, 46% of these organisms were resistant to metronidazole.
In conclusion, piperacillin-tazobactam, cefoxitin, imipenem, meropenem, metronidazole, and chloramphenicol remain active against most anaerobic isolates. The rates of resistance of Gram-positive cocci to clindamycin and moxifloxacin are variable according to species. The rates of resistance to moxifloxacin are as follows: C. difficile, 75%; anaerobic Gram-positive 
